MaxLinear and Edgecore Networks form partnership for edge networks

MaxLinear Inc. (NASDAQ: MXL) and Edgecore Networks announced a strategic partnership to develop AI-driven networking solutions for enterprise and service provider markets.

The collaboration combines MaxLinear's connectivity platforms with Edgecore's open networking systems to create infrastructure for AI workloads at the network edge. MaxLinear's multi-interface WAN solutions platform includes XGS-PON, Ethernet, and Wi-Fi capabilities with 10Gbps throughput and integrated hardware acceleration for encryption and intrusion prevention.

Edgecore contributes open infrastructure solutions including Full Stack OpenWiFi, OpenLAN switching and gateway platforms, and cloud-based management through CloudSDK. The company's Edge AI Box platform provides compute capabilities at the network edge.

The enterprise campus and edge networking market is projected to grow 7-11% annually, driven by increasing data demands and device proliferation, according to the press release.

"This partnership represents a powerful alignment of silicon innovation and system-level expertise," said Puneet Sethi, SVP & GM, Network Infrastructure & Carrier at MaxLinear. "By combining our technologies, we are enabling organizations to confidently scale their networks as they adopt AI-driven operations."

"Collaborating with partners who share a similar view of the market has always been an important part of our product strategy," said Tengtai Hsu, Vice President of Product at Edgecore Networks. "Partnering with MaxLinear is a natural next step, and we are excited about what we can build together."

MaxLinear will showcase its multi-WAN, multi-LAN security gateway at Computex Taipei 2026 from June 2-5. Edgecore Networks is a subsidiary of Accton Technology Corporation.

You May Also Be Interested In

• UWMC urges Two Harbors stockholders to reject CCM merger deal
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM
• Pfizer lung cancer drug misses survival goal in Phase 3 trial